glp-1 support stack product info and reviews META Multi Nutritional Inno Shred GLP-1 Thermogenic Fat

Anderson, MD, MAS, an assistant professor of medicine at the University of Pittsburgh, and Deborah Grady, MD, MPH, a professor emeritus of medicine and of epidemiology and biostatistics at the University of California, San Francisco, reiterated that the findings are reassuring and support preliminary data from the FDA and European Medicines Agency, but the results do not answer definitely whether or not this drug class poses safety concerns regarding mental health

January 2026: Amgen completed Phase 3 enrollment for MariTide (AMG 133) in the MARITIME-Obesity trial, with interim efficacy data expected in Q3 2026 that will position the monthly injection GLP-1/GIP antagonist as a once-monthly obesity treatment alternative

This long-term catalyst can get lost in the justifiable enthusiasm over the companys GLP-1 drugs

Here is the typical timeline, broken down by phase